Glenmark Pharmaceuticals is an Indian company that came to existence in 1977 and it is headquartered in Mumbai.
Glenmark has operations in more than 90 countries with 16 state-of-the-art manufacturing facilities in five countries and six R&D centers. The formulation business has six manufacturing facilities- 4 in India and 2 overseas.
In India, its manufacturing facilities are located in Maharashtra, Himanchal Pradesh, Goa and Gujarat while overseas facilities are located in Czech Republic and Brazil. It is operating under three business, which include:
Drug Discovery- With striking seven out-licensing deals in drug discovery and 3 R&D centers, Glenmark is the clear leader in this segment. Its effort in discovery of drugs is focused mainly in the areas of inflammation (Asthma and Arthritis), metabolic disorders (Diabetes and Obesity) and pain (Inflammatory and Neuropathic pain).
Formulation Business- This business mainly focuses on therapeutic areas such as Dermatology, Respiratory, Cardiac, Diabetes, Oncology and Gynecology.
Glenmark Generics Ltd is a subsidiary of Glenmark Pharmaceuticals which focusses on key niche segments like Dermatology, Hormones, Oncology and modified products.
Glenmark has significance presence across emerging economies in branded generics market and is enhancing its marketing network in both domestic and international markets. It is a leading player in discovering new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It heavily invests in its R&D spending around 290 crores.
Glenmark has seven molecules which are under various stages in clinical and pre-clinical trials. The molecules which are under clinical trials are Crofelemer (It can become India’s first NCE launched across emerging markets), GRC17536, GRC15300 and Vatelizumab. It has also won many awards and accolades for exceptional innovations and patents.